经皮电刺激与电针治疗纤维肌痛综合征疗效对比

目的 :对比经皮电刺激与电针治疗纤维肌痛综合征 (FS)的疗效差异。方法 :将 66例患者随机分为经皮电刺激治疗组 (A组 )、电针治疗组 (B组 )、药物对照组 (C组 )进行临床疗效的对比研究。其中A组和B组均采用以FS常见的 1 8个压痛点邻近穴位为刺激点 ,C组采用口服阿米替林为主的西药。结果 :A组及B组的有效率及痊愈显效者 6个月、1 2个月及 2 4个月随访结果同C组比较 ,其差异具有非常显著性意义 (P <0 0 1 ) ,但A组同B组比较 ,差异无显著性意义 (P >0 0 5)。结论 :经皮电刺激或电针刺激穴位治疗纤维肌痛综合征的疗效优于药物组 ,而经皮电刺激是一种无创痛且被患者乐于接受的方法     

黄芪注射液临床应用进展

目的：对黄芪注射液临床应用及其疗效进行综述。方法：通过查阅近期国内部分期刊杂志，对黄芪注射液在肺心病、老年肺结核、脑中风、冠心病、流行性出血热、病毒性心肌炎、甲亢、肝病及肾病等临床应用新进展进行综述。结果：黄芪注射液辅助治疗上述疾病疗效满意。结论：黄芪注射液是治疗心脑血管疾病、肾病、肝病等的有效药物。     

一期手术矫治肾输尿管重复畸形合并异位输尿管囊肿

目的 探讨分析完全性肾输尿管重复畸形合并同侧上输尿管异位囊肿的病人，治疗时是否需要同时切除病变肾和输尿管囊肿。方法 对近8年来我院收治的10名完全性肾输尿臂重复畸形合并同侧上输尿管异位囊肿的病例予以总结。结果 发现其中6名初期治疗中仅切除患侧上半肾输尿管的儿童，平均术后1年都因为膀胱内囊肿增大而再次接受了输尿管囊肿切除术。另3例病人一期同时施行了上半肾输尿管切除术、膀胱内输尿管囊肿切除术和下半肾输尿管再植术，术后随访疗效良好。结论 我们认为对类似疾病应该在切除肾输尿管的同时一并切除异位输尿管囊肿。     

口服或阴道用米索前列醇用于人工流产术前宫口扩张的比较

目的 :比较在人工流产术前阴道或口服用米索前列醇后宫口扩张的临床效果。方法 :将 16 1例行人工流产术的早孕妇女分成 3组。第 1组 5 3例和第 2组 5 7例于术前 1h分别经阴道用米索前列醇和口服米索前列醇各 4 0 0 μg ,第 3组为对照组5 1例 ,术前不用任何药物。结果 :第 1组和第 2组宫口扩张有效率分别是 92 % (49/ 5 3)和 89% (5 1/5 7) ,明显高于对照组 0 (0 / 5 1,P <0 .0 1) ;前 2组术中无需使用局部麻醉 (0 / 5 3和 0 / 5 7) ,而对照组则有 74 % (38/ 5 1)的病人需加用局部麻醉 (P <0 .0 1) ;前 2组术中出血量为 (7±s 4 )mL和 (7± 3)mL ,也少于对照组 (12± 4 )mL ,差异有非常显著意义 (P <0 .0 1)。阴道用米索前列醇组与口服米索前列醇组相比 ,术中扩宫口作用差异无显著意义 (P >0 .0 5 ) ,但口服用药组不良反应多于阴道用药组。结论 :阴道用米索前列醇组、口服米索前列醇组术中扩宫口作用肯定 ,出血量小、不良反应轻 ,两者疗效相似     

NHL中HCV感染与P53表达的相关性

目的探讨非霍奇金淋巴瘤 (NHL)中丙型肝炎病毒 (HCV)的感染与P5 3表达的相关性及其意义。方法应用免疫组织化学S P法对 133例NHL和 2 5例良性淋巴组织病变 (BLPC)进行P5 3及HCVTORDJI 2 2蛋白的检测 ,对其中 5 8例NHL和全部BLPC进行HCVRNA的原位RT PCR检测。结果HCV感染阳性共 17例 (TORDJI 2 2阳性 9例 ,HCVRNA阳性 11例 ,双阳性 4例 ) ,感染阳性率为 12 8% (17/ 133) ,BLPC中HCV感染阴性 ,两组比较差异有显著性 (P <0 0 5 )。NHL中P5 3阳性 71例 (5 3 4 % ) ,BLPC中P5 3均为阴性。 17例HCV阳性NHL中P5 3阳性 13例 (P <0 0 5 )。结论 (1)HCV感染与NHL之间有相关性 ;(2 )HCV可能通过调控P5 3的表达而参与NHL的发生。     

Anti-inflammatory effect of methoxyphenamine compound in rat model of chronic obstructive pulmonary disease

AIM: To evaluate the anti-inflammatory effect of methoxyphenamine compound (MC) on chronic obstructive pulmonary disease (COPD) in rats by measurement of proinflammatory cytokines, total and differential white cell counts (WCC) of bronchroalveolar lavage fluid (BALF). METHODS: Adult rat model of COPD (COPD group) was induced by intratracheal instillation of lipopolysaccharides and exposure to cigarette smoke. Treatment groups received different dosage of MC (3, 9, and 27 mg daily, MC group) or prednisone (0.25 mg daily, P group) respectively. Tumor necrosis factor alpha (TNF-α), interleukin 1beta (IL-113), interleukin-6 (IL-6), transforming growth factor β (TGF-β) of BALF were determined by ELISA. Total and differential WCC were performed after Giemsa staining. RESULTS: The levels of TNF-α, IL-1β, IL-6, TGF-β, total and differential WCC in BALF of MC groups were significantly decreased than that of COPD group (P<0.01), and there was no significant difference among MC groups. There was no significa     

瘤内注射重组人p53腺病毒治疗晚期肺癌临床试验观察

目的 观察重组人p53腺病毒注射液(rAd-p53)在晚期肺癌治疗中的疗效和毒副反应。方法 12例IIIb-IV期肺癌及3例肺转移癌,CT定位经皮肺穿刺瘤内注射rAd-p53,1 次/周×4/疗程;通过临床观察、CT及病理对照及短期随访进行评价。结果 治疗后2 月观察肿瘤缩小5例(33.3%),无变化7例(46.7%),增大3例(20%);治疗后病理观察:癌组织坏死,癌细胞稀少(6/11,54.5%);除自限性发热外,无明显毒副反应。结论rAd-p53瘤内注射治疗肺癌,无明显毒副作用,能较好地抑制局部肿瘤的发展,尤其对失去手术机会,不能耐受放化疗的患者,是一种可行的有前景的方法。     

NP与MNP方案治疗NSCLC近期疗效及毒性的对比分析

目的 :对比观察二药和三药联合化疗方案治疗非小细胞肺癌 (NSCLC)的近期疗效和毒性反应。方法 :6 2例初治的Ⅲb～Ⅳ期NSCLC ,随机分成A组 (去甲长春新碱 2 5mg/m2 静注第 1、8天 +顺铂 80mg/m2 静滴 ,分 2天 ,即NP方案 )、B组 (丝裂霉素 6mg/m2 静注第 1天 +去甲长春新碱 2 5mg/m2 静注第 1、8天 +顺铂 80mg/m2 静滴 ,分 2天 ,即MNP方案 )两组 ,分别化疗 2周期 ,每 4周为一周期。结果 :A组有效率为 33 3%、B组有效率为 37 9% (P >0 0 5 ) ;血小板降低A组为33 3% ,B组为 5 8 6 % (P <0 0 5 )。两组其余毒性反应无显著差异。结论 :二药联合可能比三药联合毒性低 ,而有效率无显著差异。     

胃粘膜瓣成型预防食管胃吻合术后反流的观察

目的:介绍胃粘膜瓣成型预防食管胃吻合术后反流的临床应用.方法:食管、贲门癌50例,行部分食管部分胃切除,用吻合器作食管胃吻合后行胃粘膜瓣成型.结果:成型组术后无反流症状,上消化道造影及放射性核素显像表明该手术方法抗反流作用明显.食管镜检查示胃粘膜瓣成型组吻合口粘膜充血、水肿、糜烂、溃疡较常规手术组明显减轻.结论:胃粘膜瓣成型术可有效预防食管胃吻合术后胃食管反流.     

Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study.

PURPOSE: To compare the effectiveness and side effects of methadone and morphine as first-line treatment with opioids for cancer pain. PATIENTS AND METHODS: Patients in international palliative care clinics with pain requiring initiation of strong opioids were randomly assigned to receive methadone (7.5 mg orally every 12 hours and 5 mg every 4 hours as needed) or morphine (15 mg sustained release every 12 hours and 5 mg every 4 hours as needed). The study duration was 4 weeks. RESULTS: A total of 103 patients were randomly assigned to treatment (49 in the methadone group and 54 in the morphine group). The groups had similar baseline scores for pain, sedation, nausea, confusion, and constipation. Patients receiving methadone had more opioid-related drop-outs (11 of 49; 22%) than those receiving morphine (three of 54; 6%; P =.019). The opioid escalation index at days 14 and 28 was similar between the two groups. More than three fourths of patients in each group reported a 20% or more reduction in pain intensity by day 8. The proportion of patients with a 20% or more improvement in pain at 4 weeks in the methadone group was 0.49 (95% CI, 0.34 to 0.64) and was similar in the morphine group (0.56; 95% CI, 0.41 to 0.70). The rates of patient-reported global benefit were nearly identical to the pain response rates and did not differ between the treatment groups. CONCLUSION: Methadone did not produce superior analgesic efficiency or overall tolerability at 4 weeks compared with morphine as a first-line strong opioid for the treatment of cancer pain.